Viridian Therapeutics Inc

NASDAQ:VRDN  
17.87
+0.51 (+2.94%)
Earnings Announcements

Viridian Therapeutics Reports 2020 Financial Results And Provides Corporate Updates

Published: 03/25/2021 20:22 GMT
Viridian Therapeutics Inc (VRDN) - Viridian Therapeutics Reports 2020 Financial Results and Provides Corporate Updates.
Q4 Revenue $100,000 Versus Refinitiv Ibes Estimate of $80,000.
Q4 Loss per Share $23.07.
Q4 Earnings per Share Estimate $-0.61 -- Refinitiv Ibes Data (analyst estimates).
Cash, Cash Equivalents and Short-term Investments Were $127.6 Million As of Dec 31, 2020, Versus $26.8 Million As of Dec 31, 2019.
Believe Current Cash, Cash Equivalents and Short-term Investments Will Be Sufficient to Fund Operations Into H2 2023.
Revenue is expected to be $0 Million
Adjusted EPS is expected to be -$0.70

Next Quarter Revenue Guidance is expected to be $0 Million
Next Quarter EPS Guidance is expected to be -$0.68

More details on our Analysts Page.